Board of Directors and Management Subscribe for units in the ongoing rights issue
September 6, 2019, Uppsala, Sweden – Dicot AB (publ) (“Dicot”) announces that all of its board of directors and parts of management will subscribe for a total of SEK 695 600 in the ongoing rights issue of units (the “Rights Issue”).
The founder and board member of Dicot, Jarl Wikberg, will subscribe for units corresponding to an amount of SEK 500 000. In addition, the other members of the Board and management in Dicot will subscribe for units corresponding to an amount of SEK 195 600. In total, Dicot's Board and management will subscribe for an amount of SEK 695 600, corresponding to 3,4 percent of the ongoing Rights Issue.
Summary of the Terms in the Rights Issue
- All existing shareholders receive one (1) unit right for each share held on the record date of August 30, 2019. One (1) unit right entitles the owner to subscribe for one (1) unit. One (1) unit contains one (1) new share and one (1) warrant. The subscription price is SEK 2.60 per unit.
- The subscription period for subscription of units will be from September 3, 2019 to September 17, 2019.
- The subscription period for subscription of shares using warrants will be from October 1, 2020 to October 15, 2020.
- The subscription price for subscription of shares using warrants will correspond to 70 percent of the average volume-weighted price of the Company's share according to Spotlight Stock Market's official list during the period from September 14, 2020 up to and including September 25, 2020. However, the subscription price shall not be lower than SEK 2.60 or higher than SEK 5.20.
Dicot has received subscription commitments amounting to 21,2 percent of the Rights Issue and guarantee commitments amounting to 48,8 percent of the Rights Issue. Thus, 70 percent of the Rights Issue is covered by subscription commitments or guarantee commitments.
Timetable for the Rights Issue
September 17, 2019: last day for subscription in the Rights Issue
September 20, 2019: indicative date for announcement of results of the Rights Issue
For further information, please contact:
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin™, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.